First Study of Intranasal Glutathione Yields Positive Results

Lourdes Salvador's Column ...Co-founder of MCS America discusses the latest Multiple Chemical Sensitivity issues.

Lourdes Salvador is the founder of MCS America, a science writer, and a social advocate for the greater awareness of environmental contamination, human toxicology, and propagation of multiple chemical sensitivity (MCS) as a disorder of organic biological origin induced by toxic environmental insults.

For more information visit MCS America

 

First Study of Intranasal Glutathione

Health Impacts of Wood Smoke Devalues Real EstateHealth Impacts of Wood Smoke Devalues Real EstateHealth Impacts of Wood Smoke Devalues Real Estate

by Lourdes Salvador

 

 

Intranasal glutathione has been recommended in a number of protocols for the treatment of chemical sensitivity, most notably by Dr. Grace Ziem. It has also been recommended in other forms by other doctors.

Researchers at Bastyr University Research Institute in Kenmore, WA confirm that glutathione depletion has been documented in several disease states. They conducted a study to test the theory that intranasal glutathione has therapeutic potential.

“In an effort to reach target tissues of the sinuses and central nervous system (CNS), glutathione is being prescribed as an intranasal spray, although no literature exists to support this mode of administration,” says lead researcher Mischley. This survey was designed to assess patient perception of intranasal glutathione tolerability, adverse events, and health benefits.

Three hundred subjects were surveyed from a pharmacy database where they purchased intranasal glutathione prescriptions. Of the 300, 70 patients in 20 states participated.

Almost half of the subjects were taking intranasal glutathione for multiple chemical sensitivity, followed closely by allergies/sinusitis. The remaining subjects were taking it for Parkinson disease, Lyme disease, fatigue, or other reasons.

A positive experience with as reported by 78.8%, while only 12.1% reported having experienced adverse effects. Health benefits were reported by 62.1%.

This first study evaluating patient-reported outcomes of prescribed intranasal glutatione has overall positive results. Side effects were insignificant.

The researchers conclude that intranasal glutathione, “should be further evaluated as a method of treating respiratory and CNS (central nervous system) diseases where free-radical burden is a suspected contributor to disease progression.

 

Reference:

Mischley LK, Vespignani MF, Finnell JS. Safety Survey of Intranasal Glutathione. J Altern Complement Med. 2012 Dec 16. PMID: 23240940 [Epub ahead of print]

 

 

For more articles on this topic, see: MCSA News.

 

Copyrighted 2012 Lourdes Salvador & MCS America

 

 

Multiple Chemical Sensitivity Forums